Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Optinose Inc (OPTN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 270,868
  • Shares Outstanding, K 41,228
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,900 K
  • 36-Month Beta 0.25
  • Price/Sales 67.11
  • Price/Cash Flow N/A
  • Price/Book 2.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.84
  • Number of Estimates 2
  • High Estimate -0.79
  • Low Estimate -0.88
  • Prior Year -0.64
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.72 +14.86%
on 12/24/18
7.83 -16.09%
on 01/08/19
+0.56 (+9.32%)
since 12/21/18
3-Month
5.66 +16.08%
on 12/21/18
12.05 -45.48%
on 11/07/18
-4.27 (-39.39%)
since 10/22/18
52-Week
5.66 +16.08%
on 12/21/18
30.00 -78.10%
on 07/09/18
-12.70 (-65.91%)
since 01/22/18

Most Recent Stories

More News
Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of eBay Inc. (NASDAQ:EBAY),...

DSGX : 30.02 (-0.43%)
EOLS : 16.24 (+1.63%)
EBAY : 32.90 (+6.13%)
PLSE : 11.78 (-3.76%)
WB : 52.51 (-13.63%)
OPTN : 6.57 (-8.37%)
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals,...

OPTN : 6.57 (-8.37%)
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today the enrollment of the first patient in a global clinical...

OPTN : 6.57 (-8.37%)
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...

OPTN : 6.57 (-8.37%)
OptiNose (OPTN) Reports Q3 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 10.29% and 21.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

OPTN : 6.57 (-8.37%)
OptiNose: 3Q Earnings Snapshot

YARDLEY, Pa. (AP) _ OptiNose Inc. (OPTN) on Tuesday reported a loss of $25.1 million in its third quarter.

OPTN : 6.57 (-8.37%)
Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018

Conference Call and Webcast Scheduled for Tuesday, November 13 at 8:00 a.m. Eastern Time

OPTN : 6.57 (-8.37%)
Optinose to Highlight Data at Two Upcoming Scientific Meetings

YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that...

OPTN : 6.57 (-8.37%)
Optinose to Present at the 2018 Cantor Global Healthcare Conference

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present...

OPTN : 6.57 (-8.37%)
New Study of Option Care Data Suggests Improved Survival for Heart Failure Patients Receiving Home Infusion of Inotropic Therapy When Coupled with Guideline-Directed Medical Therapy

Survival may improve when advanced heart failure patients receiving home infusion of inotropic therapy are also receiving guideline-directed care, suggest results of a large study recently...

OPTN : 6.57 (-8.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade OPTN with:

Business Summary

OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and...

See More

Key Turning Points

2nd Resistance Point 7.44
1st Resistance Point 7.00
Last Price 6.57
1st Support Level 6.34
2nd Support Level 6.12

See More

52-Week High 30.00
Fibonacci 61.8% 20.70
Fibonacci 50% 17.83
Fibonacci 38.2% 14.96
Last Price 6.57
52-Week Low 5.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar